|
|
|
|
|
|
by abowlofpetunias
2927 days ago
|
|
|
>There’s little evidence that ALS patients, especially those with advanced disease, will benefit from NurOwn. In BrainStorm’s Phase 2 study, NurOwn was unable to slow the progression of ALS compared with a placebo. The company turned to a responder analysis to eke out a signal of efficacy, which it’s now trying to confirm in the Phase 3 study. Here, you seemed to have missed this part. |
|
|